Tardive tremor (TT) is a rare neuroleptic-induced tardive syndrome. It is mainly postural and action associated rather than resting tremor without other parkinsonian features and resistant to most therapeutic interventions. Tetrabenazine (TBZ) is a possible option for treating TT.This study aimed to evaluate the efficacy and tolerability of TBZ in elderly patients with TT. Patients (N = 10) received TBZ (25-150 mg/d) for 6 weeks. Five subjects completed the study. Mean TBZ dose at study end was 57.5 ± 37.3 mg/d. Mean Abnormal Involuntary Movement score was 13.3 ± 6.6, mean Tremor Scale score was 2.3 ± 0.9, mean Clinical Global Impression-Change was 3.6 ± 2.2, and mean Geriatric Depression Score was 5.2 ± 4.9; all not significantly changed from baseline. Five patients suffered side effects, including depression (n = 3), parkinsonism (n = 2), akathisia (n = 1), and mild stroke (n = 1).This prospective study does not support TBZ treatment for TT in elderly psychiatric patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNF.0000000000000061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-induced parkinsonism: diagnosis and treatment.
Expert Opin Drug Saf
December 2024
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Introduction: Drug-induced parkinsonism (DIP) is one of the most common iatrogenic movement disorders. It is characterized by tremors, slowness of movement, and shuffling gait with postural instability, clinically indistinguishable from idiopathic Parkinson's disease. Prior exposure to antipsychotic medications or other dopamine receptor blocking agents (DRBAs) is required for the diagnosis.
View Article and Find Full Text PDFChronic Cocaine Use and Parkinson's Disease: An Interpretative Model.
Int J Environ Res Public Health
August 2024
VP Dole Research Group, G. De Lisio Institute of Behavioural Sciences, Via di Pratale 3, 56121 Pisa, Italy.
Article Synopsis
- Cocaine use has become a significant public health issue, with roughly 24.6 million users globally and 1 million diagnosed with cocaine use disorder, according to the 2023 World Drug Report.
- While short-term effects of cocaine are well-documented, there is a lack of comprehensive data on its medium and long-term impacts, which suggest increased risks for cardiovascular issues and neurodegenerative diseases.
- The paper proposes that chronic cocaine use leads to neurobiological changes affecting neurotransmitter systems, particularly dopaminergic pathways, which may increase vulnerability to neurodegenerative disorders and highlights the need for further research to inform therapeutic interventions.
Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database.
Expert Rev Gastroenterol Hepatol
July 2024
Center for Advanced Therapeutic Endoscopy (CATE), Porter Adventist Hospital/PEAK Gastroenterology, Denver, CO, USA.
Article Synopsis
- The study investigates adverse drug reactions (ADRs) for metoclopramide and prucalopride, both used for gastrointestinal issues, using the FDA's Adverse Event Reporting System (FAERS) data from January 2013 to December 2023.
- Key ADRs for metoclopramide include tardive dyskinesia (36.2%), dystonia (15.7%), and serious heart risks like Torsade de pointes, while prucalopride commonly causes headaches (13.9%), diarrhea (13.4%), and abdominal pain (11.6%).
- The findings suggest that both drugs carry significant risks for serious side effects, with metoclop
Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.
Gen Hosp Psychiatry
September 2024
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China. Electronic address:
Purpose: Valbenazine is commonly used to treat tardive dyskinesia, and we conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) to evaluate neurological safety signals associated with valbenazine.
Methods: Data was collected in FAERS from the second quarter of 2017 to the fourth quarter of 2023 for data cleaning. Neurological adverse event (AE) signals of valbenazine were mined by calculating reporting odds ratios (ROR), information component (IC) and empirical Bayesian geometric mean (EBGM).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!